Johnson v. Glaxo Smith Kline

214 F.R.D. 416, 2002 WL 32074878
CourtDistrict Court, S.D. Mississippi
DecidedMarch 29, 2002
DocketCiv.A. No. 5:01-CV-160
StatusPublished
Cited by8 cases

This text of 214 F.R.D. 416 (Johnson v. Glaxo Smith Kline) is published on Counsel Stack Legal Research, covering District Court, S.D. Mississippi primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Johnson v. Glaxo Smith Kline, 214 F.R.D. 416, 2002 WL 32074878 (S.D. Miss. 2002).

Opinion

MEMORANDUM OPINION AND ORDER

BRAMLETTE, District Judge.

This cause is before the Court on the plaintiffs’ motion to remand (docket entry 7). Also pending is defendant Joseph N. Bailey, III, M.D.’s motion to sever (docket entry 5-1) and to change venue (docket entry 5-2), which is not properly before the Court at this time. Having carefully considered the plaintiffs motion, the response, briefs, applicable statutory and case law, and being otherwise fully advised in the premises, the Court finds as follows:

In March of 2001, the plaintiffs commenced this action by filing a Complaint in the Circuit Court of Jefferson County, Mississippi. The plaintiffs seek damages for physical and emotional injuries claimed to have been proximately caused by their ingestion of the prescription drug Lotronex, intended for the treatment of irritable bowel syndrome. They have sued the manufacturer of Lotro-nex, Glaxo SmithKline, f/k/a Glaxo Wellcome, Inc. (the corporate entity is presently known as SmithKline Beacham Corporation, and will be referred to as “SKB”), for strict liability, negligence, breach of warranty, and negligent misrepresentation. They have also sued Bankston Drags (“the pharmacy defendant”) for negligent misrepresentation, and doctors Headley, Borum and Bailey (“the physician defendants”) for medical malpractice. Although SKB is a foreign corporation [418]*418organized under the laws of Pennsylvania with its principal place of business in a state other than the state of Mississippi, the pharmacy defendant and physician defendants are all Mississippi residents.

SKB timely removed the case to federal court. In its Notice of Removal, SKB contends that this Court has subject matter jurisdiction pursuant to 28 U.S.C. § 1332. Although the plaintiffs, pharmacy defendant and physician defendants are Mississippi residents, SKB claims that the Court can properly exercise diversity jurisdiction over this matter because the plaintiffs fraudulently joined the pharmacy defendant, and fraudulently misjoined three of the plaintiffs’ claims against physician defendants with the remaining three plaintiffs whose claims do not name a physician defendant. The plaintiffs filed the instant motion to remand, stating that they did not fraudulently join any of the defendants, and that joinder of the plaintiffs, proper under Mississippi law, does not constitute fraudulent misjoinder. The federal removal statute permits a defendant in a state court action to remove the lawsuit to federal district court if federal subject matter jurisdiction existed when the complaint was initially filed. 28 U.S.C. § 1441(a); see Baris v. Sulpicio Lines, Inc., 932 F.2d 1540, 1546 (5th Cir.1991). In other words, removal of a case from state to federal court is proper if the case could have been brought originally in federal court. Id.

A federal district court may assert jurisdiction in a case involving citizens of different states where the amount in controversy, exclusive of interest and costs, exceeds $75,000. See 28 U.S.C. § 1332(a). The sufficiency of the jurisdictional amount is not in dispute in this case. Diversity jurisdiction requires that “none of the parties in interest properly joined and served as defendants is a citizen of the State in which such action is brought.” 28 U.S.C. § 1441(b). Complete diversity is ordinarily required in cases based on diversity of citizenship under § 1332. This requirement advances the aim of diversity jurisdiction, which is to protect out-of-state litigants against possible prejudice in favor of a local litigant. J.A. Olson Company v. City of Winona, Mississippi, 818 F.2d 401, 404 (5th Cir.1987).

A federal district court may remand a case to state court if it finds that it lacks proper subject matter jurisdiction. 28 U.S.C. § 1447(c). In considering disputes concerning jurisdiction, a “district court, in a challenged case, may retain jurisdiction only where its authority to do so is clear.” Gorman v. Abbott Laboratories, 629 F.Supp. 1196, 1203 (D.R.I.1986). A removing defendant bears the burden of demonstrating that jurisdiction properly lies with the district court, and that removal was, indeed, proper. DeAguilar v. Boeing Co., 47 F.3d 1404, 1408 (5th Cir.1995); Jernigan v. Ashland Oil Co., 989 F.2d 812, 815 (5th Cir.1993); Scott v. Communications Services, 762 F.Supp. 147, 149 (S.D.Tex.1991). The removing party’s responsibility “extends not only to demonstrating a jurisdictional basis for removal, but also necessary compliance with the requirements of the removal statute.” Albonetti v. GAF Corporation-Chemical Group, 520 F.Supp. 825, 827 (S.D.Tex.1981). A defendant’s failure to satisfy this burden requires remand. Furthermore, when doubt exists as to the right to removal in the first instance, ambiguities are to be construed against removal. Dodson v. Spiliada Maritime Corp., 951 F.2d 40, 42 (5th Cir.1992); Butler v. Polk, 592 F.2d 1293, 1296 (5th Cir.1979); Samuel v. Langham, 780 F.Supp. 424, 427 (N.D.Tex.1992); see also, Fellhauer v. Geneva, 673 F.Supp. 1445, 1447 (N.D.Ill. 1987).

When the parties are diverse and the amount in controversy is sufficient, a defendant has the statutory right to remove an action from state court and maintain the suit in federal court. See 28 U.S.C. § 1332(a). Where diversity jurisdiction otherwise exists, it “cannot be defeated by a fraudulent joinder of a residential defendant having no real connection to the controversy.” Wilson v. Republic Iron & Steel Co., 257 U.S. 92, 97, 42 S.Ct. 35, 66 L.Ed. 144 (1921). Thus, when determining whether complete diversity exists, courts shall disregard the citizenship of fraudulently joined defendants. See Tedder v. F.M.C. Corp., 590 F.2d 115, 117 (5th Cir. 1979).

In the instant case, SKB asserts that the plaintiffs fraudulently joined the non-diverse [419]*419pharmacy defendant for the purpose of defeating diversity jurisdiction. However, § 1441(b) requires that “none of the parties in interest properly joined and served as defendants is a citizen of the State in which such' action is brought” (emphasis added).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Welborn v. Ethicon Inc.
N.D. Indiana, 2022
Sandra Kirkland v. Wyeth
Eighth Circuit, 2010
Prempro Products Liability Litigation v. Wyeth
591 F.3d 613 (Eighth Circuit, 2010)
Rutherford v. Merck & Co., Inc.
428 F. Supp. 2d 842 (S.D. Illinois, 2006)
Jones v. Nastech Pharmaceutical
319 F. Supp. 2d 720 (S.D. Mississippi, 2004)
Burns v. Western Southern Life Insurance
298 F. Supp. 2d 401 (S.D. West Virginia, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
214 F.R.D. 416, 2002 WL 32074878, Counsel Stack Legal Research, https://law.counselstack.com/opinion/johnson-v-glaxo-smith-kline-mssd-2002.